Cargando…
Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study
Introduction: Convalescent plasma is a promising therapeutic option for corona virus disease 2019 (COVID-19). A recent study in 34 COVID-19 patients showed a reduction of recovered patients antibodies within 3 months of infection. The aim on this analysis was to evaluate the antibody titers and expl...
Autores principales: | Terpos, Evangelos, Politou, Marianna, Sergentanis, Theodoros N, Mentis, Andreas, Pappa, Vassiliki, Pagoni, Maria, Grouzi, Elisavet, Labropoulou, Stavroula, Charitaki, Ioanna, Moschandreou, Dimitra, Bouhla, Anthi, Saridakis, Stylianos, Korompoki, Eleni, Giatra, Chara, Bagratuni, Tina, Pefanis, Angelos, Papageorgiou, Sotirios, Spyridonidis, Alexandros, Antoniadou, Anastasia, Kotanidou, Anastasia, Syrigos, Konstantinos, Stamoulis, Konstantinos, Panayiotakopoulos, George, Tsiodras, Sotirios, Alexopoulos, Leonidas, Dimopoulos, Meletios A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330323/ http://dx.doi.org/10.1182/blood-2020-136940 |
Ejemplares similares
-
Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
por: Terpos, Evangelos, et al.
Publicado: (2020) -
Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021) -
A Multicompartment Mathematical Model Based on Host Immunity for Dissecting COVID-19 Heterogeneity
por: Wu, Jianghua, et al.
Publicado: (2021) -
Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK
por: Shields, Adrian M, et al.
Publicado: (2021) -
Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19
por: Corona De Lapuerta, Magdalena, et al.
Publicado: (2021)